Related Experiment Video
Updated: Jul 7, 2026
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Renin inhibition in hypertension
1Division of Cardiovascular Diseases, The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania 15224, USA. gradmanmd@aol.com
Journal of the American College of Cardiology
|February 2, 2008
Summary
Aliskiren, a direct renin inhibitor, effectively lowers blood pressure in hypertensive patients. This drug offers sustained control and is well-tolerated, representing a significant advance in renin-angiotensin system blockade.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Development
Background:
- Renin inhibition is a key strategy for blocking the renin-angiotensin system.
- Renin's role in angiotensin II synthesis is rate-limiting.
- The (pro)renin receptor amplifies renin's effects.
Purpose of the Study:
- To introduce aliskiren, a novel direct renin inhibitor.
- To evaluate aliskiren's efficacy and tolerability in hypertension.
- To explore aliskiren's role in combination therapy.
Main Methods:
- Molecular modeling for drug design.
- Clinical trials in hypertensive patients.
- Assessment of blood pressure reduction and plasma renin activity.
Main Results:
- Aliskiren demonstrated dose-dependent blood pressure reduction and 24-hour control.
- It exhibited placebo-like tolerability at effective doses.
- Combination therapy with diuretics or ARBs showed additive or synergistic effects.
Conclusions:
- Aliskiren is a potent and bioavailable direct renin inhibitor for hypertension.
- It provides sustained blood pressure control and is effective in combination therapies.
- Further trials will define its long-term role in cardiovascular disease management.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.